pBItetDT960GFP Citations (2)

Originally described in: RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.
Lee JE, Bennett CF, Cooper TA Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4221-6. doi: 10.1073/pnas.1117019109. Epub 2012 Feb 27. PubMed Journal

---

Articles Citing pBItetDT960GFP

Articles
CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model. Ketley A, Wojciechowska M, Ghidelli-Disse S, Bamborough P, Ghosh TK, Morato ML, Sedehizadeh S, Malik NA, Tang Z, Powalowska P, Tanner M, Billeter-Clark R, Trueman RC, Geiszler PC, Agostini A, Othman O, Bosche M, Bantscheff M, Rudiger M, Mossakowska DE, Drewry DH, Zuercher WJ, Thornton CA, Drewes G, Uings I, Hayes CJ, Brook JD. Sci Transl Med. 2020 Apr 29;12(541). pii: 12/541/eaaz2415. doi: 10.1126/scitranslmed.aaz2415. PubMed
Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy. Repellin M, Carton F, Boschi F, Galie M, Perduca M, Calderan L, Jacquier A, Carras J, Schaeffer L, Briancon S, Lollo G, Malatesta M. Nanomedicine. 2023 Jan;47:102623. doi: 10.1016/j.nano.2022.102623. Epub 2022 Oct 26. PubMed

If you have published an article using this material, please email us at to have your article added to this page.